Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: N 547; Niacinamide; Nicotinamide gel; Papulex

Latest Information Update: 03 Dec 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GenDerm Corporation; National Institutes of Health (USA); University of Washington
  • Developer Euroderma; GenDerm Corporation; University of Washington
  • Class Amides; Antiacnes; Antibacterials; Nicotinic acids; Small molecules; Vitamins
  • Mechanism of Action Cytokine modulators; JNK mitogen-activated protein kinase inhibitors; Leukocyte modulators; Mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 26 Nov 2015 Alliance Pharma plc enters into a conditional agreement to acquire Nicotinamide from Sinclair IS Pharma plc
  • 11 Nov 2011 Invida Group has been acquired by Menarini
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top